Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial
Strober B, Krueger J, Magnolo N, Vender R, Toth D, Thaci D, Wang M, Cioffi C, Madden C, Warren R. Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial. SKIN The Journal Of Cutaneous Medicine 2021, 5: s16. DOI: 10.25251/skin.5.supp.16.Peer-Reviewed Original Research